Stocks · News reference

Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress

Aug 24, 2026, 11:31 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 17, 2026, 1:37 PMBenzinga Newsdesk
Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome
REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based on clinical
Read original at benzinga
ARWR
BenzingaAug 6, 2026, 6:44 PMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.
Read original at benzinga
ARWR
BenzingaAug 4, 2026, 8:02 PMBenzinga Newsdesk
Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of $(1.26) per share from
Read original at benzinga
ARWR